Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.

Official Title

A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patients With Prion Disease

Details

This is a first-in-human, randomized, multi-center study in participants with prion disease. Eligible participants will receive ION717 and placebo. The order of doses will be randomized and blinded to participants, study sites and the Sponsor. The study will consist of a screening period of up to 6 weeks, a 24-week double-blind treatment period and a 36-week post-treatment period. Multiple dose levels will be tested.

As of April 2024, study recruitment is paused because capacity has been reached for the current stage of the study. Recruitment is anticipated to resume later in 2024.

Central Contact: Ionis Pharmaceuticals

Telephone: (844) 221-3587

Email: PrionDisease@clinicaltrialmedia.com

Keywords

Prion Disease, Prion Diseases, ION717

Eligibility

You can join if…

Open to people ages 18 years and up

  • A confirmed diagnosis of probable or definite prion disease.
  • Early-stage prion disease at the time of Screening.
  • Willing to meet all study requirements, including travel to Study Center, procedures, measurements and visits.
  • Patients must have a caregiver who is ≥ 18 years old and who is able and willing to facilitate the patient's involvement, to the best of their ability, for the duration of the trial; caregivers must also be able and willing to provide information about themselves and the patient for the duration of the trial.
  • Aged ≥ 18 at the time of informed consent.

You CAN'T join if...

  • Clinically significant abnormalities in medical history, laboratory tests or physical examination that would render a patient unsuitable for inclusion.
  • Any contraindication or unwillingness to undergo an MRI.
  • Obstructive hydrocephalus, presence of a functional ventriculoperitoneal shunt for the drainage of cerebrospinal fluid (CSF) or an implanted central nervous system (CNS) catheter.
  • Known brain or spinal disease that would interfere with the LP process, CSF circulation or safety assessment.
  • Have any other condition, which, in the opinion of the Investigator would make the patient unsuitable for inclusion or could interfere with the patient participating in or completing the study.

Locations

  • UCLA Neurology Clinic
    Los Angeles California 90095 United States
  • University of Alberta
    Edmonton Alberta T6G 2M8 Canada

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ionis Pharmaceuticals, Inc.
ID
NCT06153966
Phase
Phase 1/2 Prion Disease Research Study
Study Type
Interventional
Participants
Expecting 56 study participants
Last Updated